Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amlitelimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Phase 2b Results for Amlitelimab Show Maintenance Potential in Atopic Dermatitis
Details : KY1005 (amlitelimab) is a non-T cell depleting antibody blocking OX40-Ligand, potential first-in-class for moderate-to-severe atopic dermatitis.
Product Name : SAR445229
Product Type : Antibody
Upfront Cash : Inapplicable
November 03, 2024
Lead Product(s) : Amlitelimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant, which is used for treatment of moderate-to-severe atopic dermatitis.
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
November 07, 2023
Lead Product(s) : Dupilumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amlitelimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SAR445229 (amlitelimab) is a fully human non-depleting monoclonal antibody that binds to OX40-Ligand, potential to be a first-in-class treatment for a range of immune-mediated diseases and inflammatory disorders, including moderate-to-severe atopic derma...
Product Name : SAR445229
Product Type : Antibody
Upfront Cash : Inapplicable
June 27, 2023
Lead Product(s) : Amlitelimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis
Details : Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
November 11, 2022
Lead Product(s) : Dupilumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Adding Dupixent (dupilumab) to low-potency TCS improved skin clearance and reduced overall disease severity and itch compared to TCS alone at 16 weeks. Dupixent patients experienced improvement in measures of sleep quality, skin pain and health-related q...
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
September 16, 2022
Lead Product(s) : Dupilumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
August 09, 2022
Lead Product(s) : Dupilumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Long-term safety data from a 52-week open-label extension trial in this age group reinforce the well-established safety profile of Dupixent (dupilumab), observed across all other approved age groups.
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
July 06, 2022
Lead Product(s) : Dupilumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Presentations of analyses evaluating skin barrier function in patients 12 years and older will show Dupixent (dupilumab) normalized skin barrier function for many patients and was associated with improvements in disease signs and symptoms and quality of ...
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
June 09, 2022
Lead Product(s) : Dupilumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The safety results of the trial were generally consistent with the known safety profile of Dupixent in its approved indications. The occurrences of treatment-emergent adverse events were generally similar between Dupixent and placebo groups (57% Dupixent...
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
October 22, 2021
Lead Product(s) : Dupilumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amlitelimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In study, amlitelimab showed improvements in symptoms of moderate-to-severe atopic dermatitis with well-tolerated safety profile in adults whose disease can not be controlled with topical medications or for whom topical medications are not a recommended ...
Product Name : SAR445229
Product Type : Antibody
Upfront Cash : Inapplicable
September 30, 2021
Lead Product(s) : Amlitelimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
